Director/PDMR Shareholding

January 8, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”)

Notification of transactions by persons discharging managerial responsibilities

1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameFlemming Ornskov
2.Reason for the notification
a)Position / statusChief Executive Officer - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Portfolio Share Plan (“PSP”) on February 28, 2013.  In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$95.0445,601
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Portfolio Share Plan (“PSP”) on May 2, 2013.  In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$91.5918,984
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Portfolio Share Plan (“PSP”) on February 28, 2014.  In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$168.5434,174
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
7.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVoluntary cancellation of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 on April 30, 2015, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$7.6910,031
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
8.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the SARs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. applicable performance conditions were achieved at a level of 100%;
  3. exercise of the SARs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$161.4243,329
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
9.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. applicable performance conditions were achieved at a level of 100%;
  3. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  4. vesting of the PSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$033,023
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
10.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 11, 2016.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$04,313
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
11.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVoluntary cancellation of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 on February 28, 2017, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018. The number of SARs outstanding prior to cancellation was reduced to reflect the the achievement of applicable performance conditions at a level of 87%.
c)Price(s) and volume(s)Price(s)Volume(s)
$5.6926,566
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
12.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 28, 2017.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date and the achievement of applicable performance conditions at a level of 87%;
  3. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  4. vesting of the PSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$013,441
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
13.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 10, 2017.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$03,765
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
14.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 9, 2018.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$03,512
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
15.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on May 1, 2018.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date;
  3. applicable performance conditions were achieved at a level of 100%;
  4. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  5. vesting of the PSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$014,941
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameThomas Dittrich
2.Reason for the notification
a)Position / statusChief Financial Officer - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on March 29, 2018.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date;
  3. applicable performance conditions were achieved at a level of 100%;
  4. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  5. vesting of the PSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£02,544
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on May 1, 2018.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:

  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date;
  3. applicable performance conditions were achieved at a level of 100%;
  4. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
vesting of the PSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£016,854
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameAndy Busch
2.Reason for the notification
a)Position / statusHead of Research and Development and Chief Scientific Officer - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on March 1, 2018.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting dates resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting dates;
  3. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  4. vesting of the RSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£07,628
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on March 1, 2018.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the SARs was accelerated relative to the normal vesting dates resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of SARs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date;
  3. exercise of the SARs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£31.2911,132
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on May 1, 2018.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date;
  3. applicable performance conditions were achieved at a level of 100%;
  4. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  5. vesting of the PSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£012,584
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameJoanne Cordeiro
2.Reason for the notification
a)Position / statusChief Human Resources Officer - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Portfolio Share Plan (“PSP”) on February 28, 2014.  In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$168.54772
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVoluntary cancellation of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 on February 27, 2015, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$7.681,934
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of certain of the SARs was accelerated relative to the normal vesting dates resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. exercise of the SARs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$161.423,495
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
7.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVoluntary cancellation of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 on February 28, 2017, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$5.693,896
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
8.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 28, 2017.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date and the achievement of applicable performance conditions at a level of 87%;
  3. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  4. vesting of the PSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$0346
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
9.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 28, 2017.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date;
  3. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  4. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$0139
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
10.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on August 24, 2017.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date;
  3. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  4. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$0939
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
11.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 9, 2018.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$0825
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameBill Mordan
2.Reason for the notification
a)Position / statusGeneral Counsel and Company Secretary - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 12, 2016.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the SARs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. exercise of the SARs is to be satisfied in cash in an amount per ADS $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$154.956,147
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the SARs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. exercise of the SARs is to be satisfied in cash in an amount per ADS $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$161.429,680
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 11, 2016.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$0157
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
7.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVoluntary cancellation of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 on February 28, 2017, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$5.699,415
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
8.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 28, 2017.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date and the achievement of applicable performance conditions at a level of 87%;
  3. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  4. vesting of the PSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$05,140
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
9.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 10, 2017.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$0869
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
10.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 9, 2018.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$01,039
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
11.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on May 1, 2018.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date;
  3. applicable performance conditions were achieved at a level of 100%;
  4. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  5. vesting of the PSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$05,060
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NamePerry Sternberg
2.Reason for the notification
a)Position / statusHead of US Commercial - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Portfolio Share Plan (“PSP”) on February 28, 2014.  In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$168.541,485
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVoluntary cancellation of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 on February 27, 2015, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.  
c)Price(s) and volume(s)Price(s)Volume(s)
$7.685,909
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of certain of the SARs was accelerated relative to the normal vesting dates resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. exercise of the SARs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$161.428,896
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
7.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVoluntary cancellation of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 on February 28, 2017, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$5.699,511
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
8.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 9, 2018.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$0719
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
9.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on May 1, 2018.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date;
  3. applicable performance conditions were achieved at a level of 100%;
  4. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  5. vesting of the PSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$03,979
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
10.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Award (“RSA”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 10, 2017.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSA was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. as a result of the vesting of the RSA, restrictions applying to the applicable ADSs already held will cease to apply.
c)Price(s) and volume(s)Price(s)Volume(s)
$0530
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameKim Stratton
2.Reason for the notification
a)Position / statusHead of International Commercial - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Portfolio Share Plan (“PSP”) on August 29, 2013.  In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£24.009,787
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Portfolio Share Plan (“PSP”) on February 28, 2014.  In accordance with the rules of the PSP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018, exercise of the SARs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£33.836,590
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVoluntary cancellation of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 on February 27, 2015, in consideration of a cash payment from the Company per Ordinary Share subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
£1.6512,623
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
7.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionExercise of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of certain of the SARs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. exercise of the SARs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£38.5015,086
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
8.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. applicable performance conditions were achieved at a level of 100%;
  3. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  4. vesting of the PSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£02,136
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
9.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 26, 2016.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per Ordinary Share £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£0748
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
10.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on August 5, 2016.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date(s) resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per Ordinary Share £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£03113
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
11.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVoluntary cancellation of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 on February 28, 2017, in consideration of a cash payment from the Company per Ordinary Share subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
£1.5226,587
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
12.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 28, 2017.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date and the achievement of applicable performance conditions at a level of 87%;
  3. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  4. vesting of the PSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£014,518
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
13.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 10, 2017.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£02,957
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
14.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 9, 2018.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date(s) resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£03,915
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
15.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on May 1, 2018.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date;
  3. applicable performance conditions were achieved at a level of 100%;
  4. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  5. vesting of the PSUs is to be satisfied in cash in an amount per Ordinary Share of £47.12, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
£013,488
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameMatt Walker
2.Reason for the notification
a)Position / statusHead of Technical Operations - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVoluntary cancellation of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 on May 2, 2016, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$5.785,162
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
5.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVoluntary cancellation of Stock Appreciation Rights (“SARs”) awarded under the Shire Long Term Incentive Plan 2015 on February 28, 2017, in consideration of a cash payment from the Company per ADS subject to the SAR, net of any necessary deductions for tax and social security contributions, in accordance with the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited dated May 8, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$5.698,179
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
6.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Performance Stock Units (“PSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on February 28, 2017.  In accordance with the rules of the LTIP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the PSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of PSUs vesting was reduced to reflect the accelerated date of vesting relative to the normal vesting date and the achievement of applicable performance conditions at a level of 87%;
  3. the number of PSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting PSUs from the award date to the date of vesting;
  4. vesting of the PSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$04,466
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
7.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 10, 2017.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$0418
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A
8.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionVesting of Restricted Stock Units (“RSUs”) awarded under the Shire Deferred Bonus Plan 2015 (“DBP”) on March 9, 2018.  In accordance with the rules of the DBP and the Co-Operation Agreement between the Company and Takeda Pharmaceutical Company Limited (“Takeda”) dated May 8, 2018:
  1. vesting of the RSUs was accelerated relative to the normal vesting date resultant of the Royal Court of Jersey’s sanctioning of the scheme of arrangement governing the acquisition of the Company by Takeda;
  2. the number of RSUs vesting was increased by an amount equivalent to the value of dividends paid by the Company in respect of the vesting RSUs from the award date to the date of vesting;
  3. vesting of the RSUs is to be satisfied in cash in an amount per ADS of $173.17, net of any necessary deductions for tax and social security contributions.
c)Price(s) and volume(s)Price(s)Volume(s)
$0924
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionJanuary 3, 2019
f)Place of the transactionN/A

For further information please contact:

Investor Relations  
Christoph Brackmannchristoph.brackmann@shire.com+41 41 288 41 29
Sun Kimsun.kim@shire.com+1 617 588 8175
Scott Burrowsscott.burrows@shire.com+41 41 288 4195
   
Media  
Katie Joycekjoyce@shire.com +1 781 482 2779
   

NOTES TO EDITORS

Shire is now part of Takeda.

www.takeda.com

www.shire.com